Publication alert! - Our latest article published in Frontiers in Neuroscience.
18 JANUARY 2022
Impending Mental Health Issues During Coronavirus Disease 2019 – Time for Personalized Nutrition Based on the Gut Microbiota to Tide Over the Crisis?
Debojyoti Dhar* Leucine Rich Bio Pvt. Ltd., Bengaluru, India
Publication alert! - A new publication from our team is now listed in PubMed
04 JANUARY 2022
Analysis of microarray data from medulloblastoma tissue samples (2022).
Methods Mol Biol 2423:59-64 Dhar D* and Kallapua G* *Leucine Rich Bio Pvt Ltd
13 MAY 2020
Gut Microbiota and Covid-19-possible link and implications (2020).
Virus Res (2020) 285; 198018. Dhar D* and Mohanty A# *Leucine Rich Bio Pvt Ltd # - Rajiv Gandhi Cancer Institute and Research centre
04 JUNE 2021
Prospective Open label non-comparative single arm single centre pilot study to evaluate the effectiveness of adding KB01 in participants with IBD, IBS and ODS based on the gut microbiome analysis (2019).
World J Pharm Pharm Sci (2019), vol 8(10); 569-78 Porwal A#., Dhar D*., Gandhi P#., Kulkarni D# *Leucine Rich Bio Pvt Ltd # - Healing Hands clinic
Press Release: 10 JUNE 2021, Bengaluru
BugSpeaks adds a new interactive feature to let users check their gut health online
Leucine Rich Bio developed South Asia’s first gut microbiome test, BugSpeaks has added a new interactive feature on their site ( https://bugspeaks.com/quiz) that would allow everyone to assess the state of their gut health online for free. Various factors affect the micro-organisms residing in our intestine which in turn affect the intestinal health. This feature is in the form of a quiz/questionnaire that incorporates publicly available microbiome research information and Leucine Rich Bio’s internal data and know-how on the gut microbiota domain. The output is in the form of a score that guides the user about their state of the gut health. Although the score would indicate the state of the gut health, still for proper assessment microbiome test would be recommended.
20 MAY 2021
Leucine Rich Bio developed products BugSpeaks and Rychbiome are now available on Quickperks
We are happy to share that South Asia's first gut microbiome test - BugSpeaks and India's first gut microbiome data based nutraceutical product brand Rychbiome are now available on Quickperks App. Quickperks is one of its kind multi-brand, multi-segment loyalty program.
17 MAY 2021
Leucine Rich Bio is one of the three companies selected from India for the prestigious MassChallenge, Switzerland cohort
We are more than thrilled to share that we have been selected to participate in the @MassChallenge Switzerland 2021 accelerator program. Leucine Rich Bio was one of over 1,000 other startups to apply for the accelerator located in Lausanne, Switzerland. Looking very forward to engaging with industry experts, corporates, investors and a global community of change-makers. Stay tuned for updates and follow us on this 4-month entrepreneurship journey!
Press Release: 13 APRIL 2021, Bengaluru
South Asia’s first gut microbiome test BugSpeaks to aid stem cell transplantation patients
Leucine Rich Bio, South Asia’s first microbiome company has entered into a collaborative agreement with Dr B. S. Rajput led Scigenomics Pvt Ltd. to provide its gut microbiome test, BugSpeaks to patients undergoing stem cell transplantation and the Anti-aging treatments. Dr Rajput is a well renowned Orthopaedic and stem cells transplant surgeon based in Mumbai. Gut microbiome dysbiosis is implicated in many diseases like IBD, IBS, type2 diabetes, obesity etc. The role and impact of the gut microbiota in intestinal and hematopoietic stem cells have recently been shown in various research studies. Inflammatory disease like Osteoarthritis and Rheumatoid arthritis have also been shown to have links with the gut microbiota. Talking about the collaboration Dr Debojyoti Dhar, Co-founder and director, Leucine Rich Bio opines “the impact of the gut microbiota is now being seen in practically all diseases especially immune and inflammation-based ones. A dysbiotic gut can negatively impact lot of organs and in this context, BugSpeaks will be really a good supplementary support for patients who are undergoing stem cell therapy as this will not only provide a snapshot of the intestinal dysbiosis, if any, but will also provide actionable recommendation like personalized nutrition and supplements to take care of it. Taken together, a healthy gut may improve the efficacy and overall quality of life of the patients undergoing stem cell transplantation”. Dr Rajput is an expert stem cell transplant surgeon with 35 years of experience and he believes that new treatment modalities require advanced and next generation tools and services. He is the founder of Scigenomics (www.scigenomics.in) which would provide healthcare facilities ranging from cutting edge investigations to definitive treatment of various intractable diseases . He says “a combination of high-tech investigations like Bugspeaks and personalized cellular therapies can give miraculous results in no option diseases like Amyotropic lateral sclerosis, Rheumatoid Arthritis and interstitial lung disease. He further says that with the establishment of Gut-Lung axis , the microbiome investigation can help a lot of COVID patients , where post COVID syndrome is posing a big problem. Dr Rajput also emphasize that Anti-aging is currently the subject of attention globally where aim is prevention of diseases with disease free longer life. In such cases Bugspeaks would be part of all assessment protocols and cell therapy would be of treatment protocols.”
08 FEBRUARY 2021
Dr Debojyoti Dhar, Cofounder, Leucine Rich Bio was invited for a discussion on the role of gut health and nutrition in health and wellness especially in the Covid19 era.
The program was aired by Deutsche Welle (DW TV) – Germany’s international broadcaster as part of their Covid19 special coverage.
17 DECEMBER 2020
BugSpeaks live stream series, Microbiome Gazers episode 9 will be live streamed on 19th December, 2020 at 11 AM
The title of the episode - "Role of gut health in cancer". Dr Debojyoti Dhar, Co-founder and Director, Leucine Rich Bio will be in conversation with Shruti Sethi, well renowned fashion designer, health coach and cancer warrior.
To register please follow this link:https://www.airmeet.com/e/31105e20-4036-11eb-97d4-e39bda2122ac
11 DECEMBER 2020
"Dr Debojyoti Dhar, Director, Leucine Rich Bio Pvt Ltd was featured in Voice of Healthcare story on Idea Leaders in Healthcare"
GOING MICRO FOR MACRO BREAKTHROUGHS
India’s Microbiome Man Dr Debojyoti Dhar is looking within - all the way into the microbiomes that swim inside the human system - for answers to some of healthcare’s biggest problems. The real legacy of COVID-19 - the pandemic that threw the planet out of gear in a way never imagined possible – isn’t the poignant loss of lives (which remains heartrending) or the heroic tales of frontline warriors (which will go down in history as legend). It is the vulnerability of healthcare as a sector to the vagaries of nature. How prepared really are we for the next coronavirus, therefore? Silent crusades of firm willed visionaries like Dr. Debojyoti Dhar - unfurling in microbiology labs where scientists burn the midnight oil in quest of the next big breakthrough - assure us that at least efforts are on in full earnest. Read more
02 NOVEMBER 2020
BugSpeaks live stream series, Microbiome Gazers episode 7 will be live streamed on 5th November, 2020.
The title of the episode - "FMT or fecal microbiota transplantation - past, present and future" . Dr Debojyoti Dhar, Co-founder and Director, Leucine Rich Bio will be in conversation with Dr Siba Dolai, Australia. Dr Dolai is the Principal Scientist, Centre for Digestive Diseases, Sydney, Australia.
To register please follow this link:https://www.airmeet.com/e/66c5f9c0-1ab7-11eb-a69f-694f61e413c8
24 OCTOBER 2020
BugSpeaks live stream series, Microbiome Gazers episode 6 will be live streamed on 30th October, 2020.
BugSpeaks live stream series, Microbiome Gazers episode 6 will be live streamed on 15th October, 2020. The title of the episode - "Role of gut microbiota in gastrointestinal diseases - A clinician's perspective with Dr Ashwin Porwal". Dr Porwal, well renowned proctologist and founder of Healing Hands clinic will be in conversation with Dr Debojyoti Dhar, Co-founder and Director, Leucine Rich Bio.
To register please follow this link:https://www.airmeet.com/e/32e11250-14fb-11eb-927c-01a1ada5877b
14 OCTOBER 2020
BugSpeaks live stream series, Microbiome Gazers episode 4 will be live streamed on 15th October, 2020
BugSpeaks live stream series, Microbiome Gazers episode 4 will be live streamed on 15th October, 2020. The title of the episode - "Role of the microbiome - A clinician's perspective". Dr Shabnam Das Kar, well renowned functional and metabolic medicine expert will be in conversation with Dr Debojyoti Dhar, Co-founder and Director, Leucine Rich Bio.
To register please follow this link:https://www.airmeet.com/e/2db81750-084f-11eb-8bbf-3b2d644d583f
24 July 2020
PRESS RELEASE: Leucine Rich Bio launches BugSpeaks® Package. Bengaluru, India
Leucine Rich Bio Pvt Ltd., South Asia’s first microbiome company has launched South Asia’s first gut microbiome test - BugSpeaks® in a new avatar. The test will now be called as a package that will include a slew of benefits for the consumer. The package highlights the various inclusions that will help the end user get more value for his investment into this one of its kind unique health test. The package not only includes the BugSpeaks test report which provides unique insights into the gut microbiota and actionable recommendation to improve gut health but also addons from partner companies like Nutritatva (healthy foods) and My22BMI (personalized nutritional coaching).
The unique BugSpeaks® microbiome report contains the following insights:-
- Disease susceptibility (non-diagnostic):Gut microbiome has been found to be associated with many diseases. Developed on a patent pending matrix, the report provides an insight on the possible susceptibility of various diseases based on the gut microbiota profile of the individual. This will help the person to take necessary preventive and curative measures and can hence improve the overall health.
- Personalized nutritional recommendation:It is now understood that imbalance in the gut microflora can lead to various diseases. Since food can modulate gut microflora, it is important to translate that knowledge to practise. The report provides personalized nutritional recommendations that are based on the gut microbiota present in an individual. The unique three phase nutritional recommendation can help improve the overall gut health.
- Supplement recommendation:Probiotics and prebiotics are known to improve gut microbiota profile. But having the right ones and in the right quantity can do the trick. The report provides personalized guidance as to which probiotics are actually needed by the individual. We also provide the natural sources of the probiotics, if any.
- Gut microbiome index (GMI):A unique offering based on a patent pending matrix that provides a snapshot of the microbial gut health. Better the score, better is the gut microbial health!
Apart from the above test report with unique insights, the end user will be able to avail the following:-
- Special discount for Buying healthy food:BugSpeaks package will include discount coupons for buying healthy food from Nutritatva. Nutritatva is a new generation food tech company which is into manufacturing of nutritionally balanced food
- Free consultation and special discount for nutritional diet package:My22BMI is an online digital platform for diet and nutritional planning. All BugSpeaks customers will get free consultation and discount on basic nutritional package
Leucine Rich Bio has launched three variants of the package keeping in mind the need for multiple gut microbiome tests for certain end users. The basic package includes all the above benefits and is christened as “Profile Package”. The second package variant is named as “Prospective Package” - This will entail two BugSpeaks® tests in a period of three months post the first test. This will help the customers to monitor the effect of the BugSpeaks® test recommendations and other lifestyle, drug modifications on the gut microbiome profile. The final package variant is called the “Periodic Package”- this is more like a subscription model where the end user will be able to monitor the gut microflora for the entire year and will include four BugSpeaks® tests. Customers who wish to choose Prospective or Periodic packages will get a discount on the BugSpeaks® test pricing.
17 June 2020
Dr Debojyoti Dhar, Director, Leucine Rich Bio has been invited as a guest speaker in an international webinar organized by Rotary International, Bangladesh. He will be speaking on the topic - "Can microbes in our intestine define our health?".
BugSpeaks live stream series, Microbiome Gazers episode 4 will be live streamed on 15th October, 2020. The title of the episode - "Role of the microbiome - A clinician's perspective". Dr Shabnam Das Kar, well renowned functional and metabolic medicine expert will be in conversation with Dr Debojyoti Dhar, Co-founder and Director, Leucine Rich Bio.
25 May 2020
Express Healthcare (a unit of The Indian Express), No.1 Business News Magazine for the healthcare industry has covered our publication in Virus Research.
Dr Debojyoti Dhar, Director, Leucine Rich Bio explains the various aspects of the research in the field of gut microbiota and Covid-19.
13 May 2020
Dr Debojyoti Dhar, Director, Leucine Rich Bio has published a review on the possible role of the gut microbiota and its implications in Covid-19 in Virus Research, an international peer reviewed journal of repute. Gut microbiota and Covid-19- possible link and implications
Debojyoti Dhar* and Abhishek Mohanty, Virus Research (In Press)- https://doi.org/10.1016/j.virusres.2020.198018 *Corresponding Author, Leucine Rich Bio Pvt Ltd.
09 February 2020
Leucine Rich Bio in association with Infilife healthcare will be at Ayusmat healthcare summit 2020 organized at IIM Bengaluru on 9th February 2020
06 February 2020
Leucine Rich Bio is participating at BioAsia 2020, Hyderabad, India. Please visit us at stall S56 to learn about the exciting developments taking place at LRB and know more about South Asia's first gut microbiome test - BugSpeaks
29 January 2020
Leucine Rich Bio developed South Asia's first gut microbiome test - BugSpeaks was instrumental in a study conducted by Healing Hands clinic, Pune. This got covered in Times of India.
09 January 2020
Dr Debojyoti Dhar, Director, Leucine Rich Bio was invited as a key note speaker at the Synthetic Bio summit organized by Reliance industry. He delivered a lecture on "Microbiome domain, an advance biology for better healthcare, its impact on bioeconomy and challenges in India".
07 January 2020
Daivik wellness and LRB sign MoU to promote BugSpeaks
BugSpeaks® - South Asia's first gut microbiome test developed by Leucine Rich Bio will be distributed by well known wellness company Daivik Wellness which also operates Reset wellness centres across India.
11 December 2019
"Leucine Rich Bio is in the top 20 list of Indegenous medical devices/Diagnostics companies in India in a survey conducted by Biospectrum magazine with the highest percentage of growth year on year!"
16 October 2019
"Leucine Rich Bio has won the prestigious Frost & Sullivan award for Microbiome diagnostic tecnology innovation, 2019"
03 October 2019
"Dr Debojyoti Dhar, Director, Leucine Rich Bio Pvt Ltd. was an invited speaker at the Direct to consumer meeting held in Mumbai on 1st October 2019. He delivered a talk titled - "Dawn of a new paradigm in healthcare & wellness - Enter the world of gut microbiota"
27 September 2019
Leucine Rich Bio and VaidhyaMegha announce partnership to enhance the role of Artificial intelligence, cloud computing features to genomics and big data applications
Leucine Rich Bio, South Asia’s first microbiome company and a pioneer in microbiome and genomics has partnered with VaidhyaMegha, a Bengaluru, India based IT firm focused on health, data, cloud and analytics to bring cutting edge AI, KnowledgeGraph and algorithmic based solutions to genomics and big data application especially pertaining to human health. This partnership will enable the use of the deep knowledge experience and expertise of these individual companies to bring novel solutions.
01 August 2019
"SuperStartUp Asia Award 2019."
"Leucine Rich Bio, South Asia’s first microbiome company is the proud winner of SuperStartups Asia 2019 award. Superstartups 2019 is Asia’s largest democratically voted startup award. The award event was held at India Habitat Centre, Delhi on 1st August 2019. We thank everyone including the eminent jury for their support and well wishes! Leucine Rich Bio now joins the league of other illustrious startups - Byju’s, PhonePe, Droom, Coverfox, NetMeds, Licious and Innov8 who had won this award previously!"
11 June 2019
"Leucine Rich Bio collaborates with HCG hospital and Strand life science for an oral microbiome study in cancer."
Leucine Rich Bio, South Asia’s first microbiome company is proud to associate with Dr. Vishal Rao (Head and Neck Surgical Oncologist) from HealthCare Global, one of India’s leading cancer care hospitals, and Strand Life Sciences, to conduct an oral microbiome study in cancer patients. We hope this partnership will help elucidate some key findings that aid understanding Non tobacco oral cancer causes, diagnosis and impact treatment of oral cancer in the future.
20 March 2019
"Leucine Rich Bio has on-boarded Delhi based MY22BMI on to its "our experts section" of the consumer focused gut microbiome website -www.bugspeaks.com"
18 March 2019
"Leucine Rich Bio has on-boarded Bangalore based Better For Life on to its "our experts section" of the consumer focused gut microbiome website -www.bugspeaks.com"
14 March 2020
"Leucine Rich Bio has on-boarded Bangalore based Healing Hands Clinic on to its "our experts section" of the consumer focused gut microbiome website -www.bugspeaks.com"
05 March 2019
"Leucine Rich Bio has on-boarded Bangalore based Invictus Performance Lab on to its "our experts section" of the consumer focused gut microbiome website -www.bugspeaks.com"
26 February 2019
"Leucine Rich Bio has on-boarded Bangalore based Potential health Development (PHD) on to its "our experts section" of the consumer focused gut microbiome website -www.bugspeaks.com"
21 February 2019
"Leucine Rich Bio launched the consumer focused website for its Gut microbiome test - BugSpeaks® (South Asia's First microbiome test) - www.bugspeaks.com"
21 January 2019
Leucine Rich Bio and NextGen Life Sciences enter into collaboration to market Bug Speaks® in India
Leucine Rich Bio Pvt Ltd., Bengaluru, India based, South Asia’s first microbiome focused and genomics driven company and NextGen Life Sciences Pvt. Ltd., Delhi, another India based company which provides “one stop solution” for unmatched combination of innovative technologies have entered into collaboration where in Leucine Rich Bio’s flagship gut microbiome test Bug Speaks® will be marketed through NextGen Life sciences network in India. Leucine Rich Bio developed Bug Speaks® has already been launched in India in select metros and is being currently used by gastroenterologists for their patients and people who want to improve their health by analysing their gut microbiota. Bug Speaks® utilizes patent pending algorithm and matrix including in-house curated and developed databases to generate the report which includes nutritional and probiotic recommendation to restore the gut health apart from providing information on gut microbiota and related disease susceptibilities. NextGen Life Sciences is new generation company serving Science. The company has very good network and is active in wellness domain as well and is also a distributor of many marquee original equipment and reagent manufacturers from across the world. Speaking on this tie up, Dr Debojyoti Dhar, Director, Leucine Rich Bio says “this collaboration will help Bug Speaks® to be experienced by more people in India and hopefully will help provide a new paradigm in healthcare and wellness. We also look forward to opportunities to market Bug Speaks® in other South Asian countries in near future”. Dr Nagma Abbasi, Founder & CEO of NextGen Life sciences also reverberates the same opinion “this collaboration will help us to serve towards improvement of human health and wellness in India which makes me very excited about the promising future. We are proud and highly elated to be associated with Leucine Rice Bio to Market this innovative Diagnostic tool Bug Speaks® and be part of this great initiative of improving human health”.
About Leucine Rich Bio
Leucine Rich Bio Pvt Ltd. is South Asia’s first microbiome company. The company is headquartered in Bengaluru, the Silicon Valley of India. Since its inception in 2014 the company has pioneered the development and standardization of state-of-the-art analytics tools to analyse and interpret complex genomics data. The company is also “Frost & Sullivan” award recipient (2016) for enabling technology in the cloud enabled genomics industry, Asia Pacific region. The company has launched Bug Speaks®- South Asia’s first gut microbiome test. In house developed and patent pending matrix driven interpretation engine along with in house curated databases drive the Bug Speaks®. Bug Speaks® is also part of India’s first gut microbiome based clinical trial. The key areas the company works are in preventive healthcare and precision medicine
About NextGen Life Sciences
An ISO 9001:2015 certified NextGen Life Sciences Pvt. Ltd. understands the scientific needs of the customers and brings in the table perfect solutions as the most innovative solution provider. The company bridges the gap in understanding the needs and pains of Indian Researchers of Life Science Industry and helping Scientists and Biotech Leaders to get an insight on the recent innovation and technologies assuring a sound knowledge of the subject matter of the products. NextGen Life Sciences Pvt. Ltd. since its inception in 2014 is serving Science and always strived to serve its major objective of being a leader in providing integrated, tailored solutions for life Science Researchers and Scientists. Captivated to be a single source of facility to cater the research needs of scientists in the field of Molecular biology, Cell Biology, Immunology, Healthcare, Drug Development and more, the company’s ultimate focus is driven to be One stop Solution for serving Life Science and Health care Industry. NextGen Life Sciences Featured among "Top 20 Best Life Science Start-Ups 2018" by Silicon India Magazine and also Featured as “Startup of the Year 2018” by The CEO Magazine.
06 September 2017
"Dr Debojyoti Dhar, Director, has been invited to attend "Advances in cancer research-An Indo-German Dialogue for Innovation" at Delhi on 19th September 2017.
29 June 2017
Leucine Rich Bio and Vittartha Life Science announce collaboration
Leucine Rich Bio Pvt Ltd., Bengaluru based bioinformatics driven genomics focused company has announced partnership with Vittarthaa Life Sciences, a Drug Discovery and Development company, focused on identifying unmet clinical needs to develop pharmaceuticals molecules. Leucine Rich Bio has developed cutting edge analysis and interpretation pipelines for next generation sequencing and microarray data. Apart from that the company has provided customized meta-analysis of publicly available data to cater to its client base which is spread across the globe. With strong Systems biology, molecular biology and genomics background the company can provide an umbrella of bio-informatics and other data solutions to its clients. Vittartha Life Science is a Drug / Product Discovery and Development company, focused on identifying unmet clinical/consumer needs to develop suitable and commercially viable drug/product. All Research programs are based on integrated approach towards target-based discovery strategies and phenotypic screening for end-point evaluation. It is also focused on innovative Discovery and Development approaches for progressing molecules/product into market. The discovery program devises multi-parametric, phenotypic panel assay screening efficacy that are target based and de-risk toxicity at early stages. The company engages the customer at early stages of drug/product development providing suitable platforms for mapping the molecular mechanisms that enable to create program objective, target product profile and outline milestones for go/no-go decisions. Both the companies have announced collaboration in-order to provide Pharmacuetical / Nutraceutical / Biotechnology companies a combined portfolio of research solutions under one platform. This would enable the potential clients to get maximum benefit for its research projects. Dr Debojyoti Dhar, Director, Leucine Rich Bio opines “With our association with Vitthartha we can service the Pharmaceutical / Biotechnology companies in a much more focused manner”. Dr Yogananda, Director, Vittartha Life Science also reverberates the same “Today’s global market demands a thorough molecular based approach with clinical evidence based products and drugs. Primary focus and key strengths of both the companies complement each other for today’s discovery and development. This collaboration will be mutually benefits to deliver tailor made precise requirements for every research program”.
28 February 2017
Dr. Debjyothi Dhar, Director, was invited for a talk at Chettinad Hospital & Research Institute. He delivered a lecture on “Next Generation Genomics in Research, Clinic and Beyond” on 28th FEB 2017.
07 February 2017
Leucine Rich Bio and Pytheos Health Systems announce partnership
Leucine Rich Bio Pvt Ltd., a bioinformatics driven genomics company with multi-domain interest in Research, Clinics and Healthcare/wellness has forged partnership with Pytheos Health Systems. Pytheos Health Systems offers scientific wellness and fitness programs (services) for athletes, fitness pros and wellness users. The services are orchestrated over an online digital platform which enables users to visualize, monitor and collaborate with health coaches. Leucine Rich Bio with its next generation genomics data analytics along with physician friendly clinical/wellness reporting will get a niche clientele over Pytheos health systems platforms. Pytheos operates two portals - www.MyDiagnostics.io focused on cutting edge discovery diagnostics & assessments and www.HumanFractal.io which runs end-end goal driven & persona based programs. With Leucine Rich Bio partnership, Pytheos will integrate Exome & Microbiome results to give more accurate and personalised programs to customers. The alliance will help both the companies to take the advancement in latest technologies to the customers and would help provide a bouquet of personalized services which would help the customer lead a healthy life.
31 January 2017
Leucine Rich Bio partners with Gene Express
Leucine Rich Bio Pvt Ltd., a bioinformatics driven genomics company with multi-domain interest in Research, Clinics and Healthcare/wellness has forged partnership with Gene Express Genekit distributors LLP. Gene Express (www.gene.express) is an online platform that provides all genomics services and beyond at one place. Gene express boasts some of the best European and Asian companies in its fold and has solutions for a vide range of healthcare and wellness needs. Leucine Rich Bio with its next generation genomics data analytics along with physician friendly clinical/wellness reporting will get a niche clientele over Gene Express platform. With Leucine Rich Bio’s addition on to the Gene Express platform, it will provide a bouquet of services to its clients with augmented variety and at the same time can focus on personalized healthcare solutions to the customers. Leucine Rich Bio’s foray into healthcare and wellness is natural step in the direction of providing novel genomics based solutions to its clients. Both the companies look forward to a mutually rewarding association in years to come.
20 November 2017
"Kumar Sankaran, Director, Leucine Rich Bio delivered a talk at "Frontiers in Liver Disease-2016" being held at Bengaluru at Hotel Shangri-La on 20th November.
24 October 2016
"Leucine Rich Bio Pvt Ltd. is the award recipient for the 2016 Frost & Sullivan India Award for Enabling Technology in the Cloud-enabled Genomics Industry, APAC"
BugSpeaks live stream series, Microbiome Gazers episode 4 will be live streamed on 15th October, 2020. The title of the episode - "Role of the microbiome - A clinician's perspective". Dr Shabnam Das Kar, well renowned functional and metabolic medicine expert will be in conversation with Dr Debojyoti Dhar, Co-founder and Director, Leucine Rich Bio.
04 October 2016
Leucine Rich Bio Pvt Ltd., Bengaluru based bioinformatics driven genomics focused data analysis company has announced partnership with Opex Labs India LLP a Data Platform Software Company.
The two companies would work together to develop and market newer solutions for the genomics market. Both companies’ niche area of operations and complementary capabilities provide a good opportunity to cater to the genomics domain. The Genomics domain needs newer tools which can help improve the data processing speed and better interpretation to make the analysis reliable and less time consuming. Leucine Rich bio is focused on interpretation of genomics data for clinical and research use. The company uses advances in computer science, information science, data management and systems biology to solve complex problems in genomics. The company has developed cutting edge analytics pipeline called AGIS and has also an in-house curated database of genomic variants called LRB-HGVD that provides functional information, mutation impact on disease, drug response and variant impact on protein structure and functions, with its relevant references. The main emphasis of the company is to provide the clinicians and researchers with relevant and easy to understand actionable genome clinical and ‘biologist friendly’ reports respectively.